We must be getting very close to when we find out what price BHP is going to get for its Chinese assets. The expectation was for a strong rerating for MPO when this detail was announced.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%